KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Divestments (2020 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Divestments for 6 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Divestments fell 78.95% year-over-year to $8.0 million, compared with a TTM value of $34.0 million through Dec 2025, down 20.93%, and an annual FY2025 reading of $34.0 million, down 20.93% over the prior year.
  • Divestments was $8.0 million for Q3 2025 at Teva Pharmaceutical Industries, down from $9.0 million in the prior quarter.
  • Across five years, Divestments topped out at $138.0 million in Q1 2021 and bottomed at $1.0 million in Q2 2024.
  • Average Divestments over 5 years is $30.8 million, with a median of $17.0 million recorded in 2025.
  • The sharpest move saw Divestments surged 2200.0% in 2021, then tumbled 98.21% in 2024.
  • Year by year, Divestments stood at $42.0 million in 2021, then crashed by 45.24% to $23.0 million in 2022, then tumbled by 56.52% to $10.0 million in 2023, then plummeted by 60.0% to $4.0 million in 2024, then skyrocketed by 100.0% to $8.0 million in 2025.
  • Business Quant data shows Divestments for TEVA at $8.0 million in Q3 2025, $9.0 million in Q2 2025, and $17.0 million in Q1 2025.